



Revance Therapeutics
 Investor Relations Department
 7555 Gateway Boulevard
 Newark, CA 94560
 United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: RVNC

Last Trade:	26.50
Trade Time:	1:00 PM ET Nov 24, 2017
Change:	0.45 (+1.727%)
Day Range	25.80 - 26.55
52-Week Range	15.85 - 28.75
Volume	136,215


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Revance, a Silicon Valley-based biotechnology company, is committed to the advancement of remarkable science. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS® peptide technology, which, when combined with active drug molecules, may help address current unmet needs.

Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthe... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Nov 20, 2017 [Revance Announces Orphan Drug Designation of RT002 for the Treatment of Cervical Dystonia](#)
- Nov 2, 2017 [Revance Releases Third Quarter 2017 Results](#)
- Oct 18, 2017 [Revance Therapeutics to Release Third Quarter 2017 Financial Results Thursday, November 2, 2017](#)
- Oct 18, 2017 [Revance Completes Patient Enrollment in Phase 2 Program for RT002 Injectable in the Management of Plantar Fasciitis](#)
- Sep 19, 2017 [Revance to Participate in the Cantor Fitzgerald 2017 Global Healthcare Conference](#)

Financials [\[View all \]](#)

- [Third Quarter Financial Results](#)
- Feb 28, 2017 [Annual Report \(10-K\)](#)
- Mar 24, 2017 [Proxy Statement \(DEF 14A\)](#)
- Nov 3, 2017 [Quarterly Report \(10-Q\)](#)
- Aug 4, 2017 [Quarterly Report \(10-Q\)](#)
- May 9, 2017 [Quarterly Report \(10-Q\)](#)